Oxford Biomedica Confirms Aura Biosciences Partnership For Phase 3 Eye Cancer Drug Manufacturing NASDAQ · Markets 42m ago
Fraser And Neave FY26 Attributable Profit Rises, Despite Weak Revenues; Sees Challenging FY27 NASDAQ · Markets 49m ago
SpaceX Has 33 Analysts Covering It and Just 1 "Strong Sell." Here’s What That Analyst Sees That the Other 32 Don’t. NASDAQ · Markets 58m ago
MP Materials' Earnings Report Had Multiple Bright Spots, and There's 1 Thing I'm Watching NASDAQ · Markets 1h ago